

**Catalog # 10-2626**


**Crizotinib**

CAS# 877399-52-5

PF-02341066; PF-1066

3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine

Lot # X106521



A potent and selective inhibitor of c-MET and ALK, IC<sub>50</sub>s=8 and 20 nM respectively.<sup>1</sup> Inhibition of cell proliferation was associated with G1-S phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells (IC<sub>50</sub>=30 nM) but not in ALK-negative lymphoma cells.<sup>1</sup> Exhibits cytoreductive antitumor efficacy via antiproliferative and antiangiogenic mechanisms.<sup>2</sup> Clinically useful anticancer agent.<sup>3</sup>

- 1) Christensen *et al.* (2007), *Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma*; *Mol. Cancer Ther.*, **6** 3314
- 2) Zou *et al.* (2007), *An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms*; *Cancer Res.*, **67** 4408
- 3) Bang *et al.* (2010), *Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)*; *J. Clin. Oncol.*, **28** 3

**PHYSICAL DATA**

Molecular Weight:	450.34
Molecular Formula:	C <sub>21</sub> H <sub>22</sub> Cl <sub>2</sub> FN <sub>5</sub> O
Purity:	98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (up to 25 mg/ml with warming) or Ethanol (up to 25 mg/ml with warming)
Physical Description:	White solid
Storage and Stability:	Store as supplied desiccated at -20°C for up to 1 year from the date of purchase. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months.

**Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.**